. 2022 Jun 16;29(1):1848–1862. doi: 10.1080/10717544.2022.2083725

Table 5.

Effects of EGCG Pretreatment on S. Cr level, kidney MDA level, and kidney SOD activity in cisplatin-induced nephrotoxicity in mice.

	S. Cr level (mg/dL)	Kidney MDA content (nm/g tissue)	Kidney SOD activity (U/mg tissue)
Control	1.33 ± 0.19	144 ± 14.50	2.75 ± 0.16
Cisplatin	3.52 ± 0.35^a	248 ± 14.35^a	1.25 ± 0.13^a
Free EGCG	2.21 ± 0.24^b	168 ± 9.14^b	2.15 ± 0.28^b
Placebo PLGA NCs	3.43 ± 0.32	245 ± 16.8	1.21 ± 0.14
EGCG PLGA NCs (F2)	1.65 ± 0.19^bc	150 ± 7.31^bc	2.6 ± 0.38^bc

Nephrotoxicity was induced by a single I.P. injection of cisplatin (25 mg/kg). Free EGCG or placebo PLGA NCs or EGCG PLGA NCs were given orally for 10 days.

Data expressed as mean ± SD (n = 8/group), significant difference vs. ^arespective control, ^brespective cisplatin group, and ^crespective free EGCG group each at p ˂ .05.